Postoperative Nausea and Vomiting: Ramosetron Plus Aprepitant vs Palonosetron Plus Aprepitant
NCT ID: NCT02597907
Last Updated: 2017-04-25
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
88 participants
INTERVENTIONAL
2014-07-31
2015-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Palonosetron Versus Ramosetron for the Prevention of Postoperative Nausea and Vomiting
NCT01476280
Efficacy Study of Antiemetics to Reduce Postoperative Nausea and Vomiting
NCT01806948
The Effect of Oral and Intravenous Ramosetron During Laparoscopic Cholecystectomy
NCT01041183
Therapeutic Efficacy of Ramosetron for Treatment of Established PONV After Laparoscopic Surgery
NCT03017222
The Effects of Gabapentin and Ramosetron on Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgery
NCT02617121
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study is performed during 24 hours after surgery.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
aprepitant plus palonosetron
aprepitant 80 mg palonosetron 0.075 mg
aprepitant
aprepitant 80 mg is given to all patients before surgery
palonosetron
palonosetron 0.075 mg is given to patients in the aprepitant plus palonosetron group after induction of general anesthesia
aprepitant plus ramosetron
aprepitant 80 mg ramosetron 0.3 mg
aprepitant
aprepitant 80 mg is given to all patients before surgery
Ramosetron
ramosetron 0.3 mg is given to patients in the aprepitant plus ramosetron group after induction of general anesthesia
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
aprepitant
aprepitant 80 mg is given to all patients before surgery
palonosetron
palonosetron 0.075 mg is given to patients in the aprepitant plus palonosetron group after induction of general anesthesia
Ramosetron
ramosetron 0.3 mg is given to patients in the aprepitant plus ramosetron group after induction of general anesthesia
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients with allergies to any study medication,
* Patients who had received any sedatives, opioid, steroid or antiemetics within 24 h before surgery
18 Years
65 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kyungpook National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Younghoon Jeon
Professor
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KNUH 2014-05-016
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.